Related Experiment Video
Updated: May 11, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Can dabigatran improve blood pressure control?
Vivencio Barrios1, Carlos Escobar
1Department of Cardiology, Hospital Universitario Ramón y Cajal, Ctra. Colmenar km 9.100, 28034 Madrid, Spain. vbarrios.hrc@salud.madrid.org
Insights
Drug interactions can affect blood pressure control in atrial fibrillation (AF) patients. Switching anticoagulants improved blood pressure management in a case study involving hypertension and AF.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Hypertension is a common comorbidity in atrial fibrillation (AF) patients.
- Stroke is a major complication of AF, necessitating effective blood pressure (BP) and antithrombotic management.
Observation:
- A patient with hypertension and AF experienced irregular systolic BP control.
- This was potentially linked to an interaction between the antihypertensive losartan and the anticoagulant acenocoumarol.
Findings:
- Switching the anticoagulant from acenocoumarol to dabigatran resulted in improved BP control.
- This suggests a clinically relevant interaction between losartan and acenocoumarol impacting BP management.
Implications:
- Anticoagulant and antihypertensive drug interactions warrant consideration for optimizing BP control in AF patients.
- Further investigation into these interactions may improve therapeutic strategies and reduce stroke risk.
Abstract:
Hypertension is the most frequent condition associated with atrial fibrillation (AF) and stroke, the most terrible complication of AF. Achieving blood pressure (BP) goals as well as an adequate antithrombotic treatment are critical to reduce the incidence of stroke. But are interactions between anticoagulants and antihypertensive agents relevant for achieving BP targets? We present the case of a patient with hypertension and AF in which the interaction between losartan and acenocoumarol was associated with an irregular systolic BP control, but after switching to dabigatran, BP control improved. In this report, the possible mechanisms that may explain this change are discussed.
Related Concept Videos
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Antihypertensive Drugs: Action of Diuretics
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...